EMEA-002726-PIP01-19-M01
Key facts
| Active substance |
Garadacimab
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0274/2021
|
| PIP number |
EMEA-002726-PIP01-19-M01
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of hereditary angioedema attacks
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
CSL Behring GmbH
E-mail: EU-CSLBehring@cslbehring.com
Tel: +41 795386261 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|